NOVARTIS AG NVS

Latest FY: 2025 Healthcare Drug Manufacturers - General
Market Price $137.50
Market Cap $262.36B
P/E Ratio 19.23
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑9.6% YoY
$56.67B
3-Yr CAGR: 3.0%
Net Income ↑17.0% YoY
$13.97B
Net Margin: 24.6%
Free Cash Flow ↑13.7% YoY
$1.01B
FCF Yield: 0.39%
EPS (Diluted) ↑21.8% YoY
$7.15
Basic: $7.21
Return on Equity Efficiency
N/A
ROA: 12.6%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (NVS)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $49,436.0M $31,916.0M $-14.0M 0.00% $2,111.0M $249.0M
FY 2017 $50,135.0M +1.4% $32,960.0M $7,703.0M +55,121.4% $3.17 0.00% $1,611.0M $-85.0M -134.1%
FY 2018 $53,166.0M +6.0% $34,759.0M $12,614.0M +63.8% $5.46 +72.2% 0.00% $1,670.0M $-103.0M -21.2%
FY 2019 $48,677.0M -8.4% $34,252.0M $11,737.0M -7.0% $3.08 -43.6% 0.00% $1,876.0M $497.0M +582.5%
FY 2020 $49,898.0M +2.5% $34,777.0M $8,071.0M -31.2% $3.52 +14.3% 0.00% $1,833.0M $558.0M +12.3%
FY 2021 $52,877.0M +6.0% $37,010.0M $24,018.0M +197.6% $10.63 +202.0% 0.00% $2,342.0M $964.0M +72.8%
FY 2022 $51,828.0M -2.0% $36,342.0M $6,955.0M -71.0% $2.76 -74.0% 0.00% $1,975.0M $777.0M -19.4%
FY 2023 $46,660.0M -10.0% $34,188.0M $14,854.0M +113.6% $4.10 +48.6% 0.00% $2,787.0M $1,727.0M +122.3%
FY 2024 $51,722.0M +10.8% $38,895.0M $11,939.0M -19.6% $5.87 +43.2% 0.00% $2,258.0M $892.0M -48.3%
FY 2025 $56,674.0M +9.6% $42,975.0M $13,967.0M +17.0% $7.15 +21.8% 0.00% $2,562.0M $1,014.0M +13.7%
$

Valuation

Market Price $137.50
Market Cap $262.36B
Enterprise Value N/A
P/E Ratio 19.23
P/B Ratio N/A
FCF Yield 0.39%
Dividend Yield 0.00%
Shares Outstanding 1,908,092,000
%

Profitability & Margins

Gross Margin 75.83%
Operating Margin 31.13%
Net Margin 24.64%
Return on Equity (ROE) N/A
Return on Assets (ROA) 12.59%
Asset Turnover 0.51x
Revenue 3-Yr CAGR 3.02%
🛡️

Financial Health & Liquidity

Current Ratio 0.10
Cash Ratio N/A
Debt / Equity N/A
Debt / Assets 0.000
Cash & Equivalents N/A
Total Debt N/A
Book Value / Share N/A
💧

Cash Flow Efficiency

Operating Cash Flow $2.56B
Capital Expenditures (CapEx) $1.55B
Free Cash Flow $1.01B
OCF / Revenue 4.52%
FCF / Revenue 1.79%
FCF 3-Yr CAGR 9.28%
🏷️

Per Share Metrics

EPS (Diluted) $7.15
EPS (Basic) $7.21
Dividends / Share N/A
Book Value / Share N/A
EPS YoY Growth 21.81%
🏛️

Balance Sheet (FY 2025)

Total Assets $110.95B
Total Liabilities $64.40B
Stockholders' Equity N/A
Current Assets $205.00M
Current Liabilities $1.97B